LGVN
Longeveron Inc.
Price Chart
Latest Quote
$0.75
+0.01 (+1.36%)
Current Price
| Previous Close | $0.74 |
| Open | $0.74 |
| Day High | $0.81 |
| Day Low | $0.74 |
| Volume | 62,787 |
Stock Information
| Shares Outstanding | 30.15M |
| Total Debt | $748K |
| Cash Equivalents | $15.76M |
| Revenue | $1.22M |
| Net Income | $-22.43M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $23.70M |
| EPS (TTM) | $-1.14 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $8.04M |
| Sales | $1.22M |
| Income | $-22.43M |
| Book/sh | $0.52 |
| Cash/sh | $0.52 |
| Employees | 38 |
Financial Ratios
| Quick Ratio | 3.64 |
| Current Ratio | 3.88 |
| Debt/Eq | 4.67 |
Returns & Margins
| ROA | -67.41% |
| ROE | -135.18% |
| Gross Margin | 65.13% |
| Operating Margin | -1149.50% |
Ownership
| Insider Ownership | 9.72% |
| Institutional Ownership | 14.09% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.49 |
| P/S | 19.49 |
| P/B | 1.44 |
Analyst Data
| Recommendation | none |
| Target Price | $7.15 |
Technical Indicators
| SMA20 | $0.78 |
| SMA50 | $0.83 |
| SMA200 | $0.75 |
| RSI | 42.58 |
| ATR | 0.0552 |
| Shares Float | 25.33M |
| Short Float | 7.38% |
| Short Ratio | 5.19 |
| Volatility | -0.38 |
| Rel Volume | 0.31 |
Performance History
| Week | -10.70% |
| Month | -7.51% |
| Quarter | -22.91% |
| 6 Months | +38.91% |
| YTD | +26.49% |
| Year | -39.51% |
| 3 Years | -97.99% |
| 5 Years | -98.94% |
| 10 Years | -98.99% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $0.75 | 62,787 |
| 2026-06-24 | $0.74 | 256,700 |
| 2026-06-23 | $0.80 | 129,700 |
| 2026-06-22 | $0.80 | 394,000 |
| 2026-06-18 | $0.82 | 240,900 |
| 2026-06-17 | $0.84 | 312,000 |
| 2026-06-16 | $0.77 | 83,900 |
| 2026-06-15 | $0.79 | 162,600 |
| 2026-06-12 | $0.78 | 135,300 |
| 2026-06-11 | $0.77 | 228,300 |
| 2026-06-10 | $0.77 | 133,600 |
| 2026-06-09 | $0.77 | 119,700 |
| 2026-06-08 | $0.75 | 106,900 |
| 2026-06-05 | $0.73 | 306,300 |
| 2026-06-04 | $0.80 | 175,200 |
| 2026-06-03 | $0.80 | 326,500 |
| 2026-06-02 | $0.76 | 209,600 |
| 2026-06-01 | $0.77 | 291,700 |
| 2026-05-29 | $0.77 | 181,400 |
| 2026-05-28 | $0.81 | 171,500 |
| 2026-05-27 | $0.80 | 339,800 |
| 2026-05-26 | $0.81 | 506,800 |
About Longeveron Inc.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
đ° Latest News
Longeveron Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-14T12:30:00Z
Longeveron (LGVN) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-13T22:06:37Z
Longeveron Q1 2026 Earnings Call: Complete Transcript
Benzinga âĸ 2026-05-13T21:09:05Z
Longeveron (LGVN) Q4 2025 Earnings Call Transcript
Motley Fool âĸ 2026-03-18T13:34:17Z
Longeveron Inc. Q4 2025 Earnings Call Summary
Moby âĸ 2026-03-18T12:30:00Z
Earnings To Watch: Longeveron Inc (LGVN) Reports Q4 2025 Results
GuruFocus.com âĸ 2026-03-16T13:21:18ZA $30 Million Reason to Buy Penny Stock Longeveron Today
Barchart âĸ 2026-03-11T13:00:02Z
BC-Most Active Stocks
Associated Press Finance âĸ 2026-03-10T14:30:19ZLongeveron (LGVN) Secures Rights to Stem Cell Patent for Cardiac Treatment
Insider Monkey âĸ 2025-08-29T11:25:28Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $396,000 | $508,000 | $488,000 | $725,000 |
| Cost Of Revenue | $396,000 | $508,000 | $488,000 | $725,000 |
| Total Revenue | $1,199,000 | $2,392,000 | $709,000 | $1,222,000 |
| Operating Revenue | $1,199,000 | $2,392,000 | $709,000 | $1,222,000 |
| Expenses | ||||
| Total Expenses | $24,486,000 | $18,914,000 | $21,738,000 | $19,265,000 |
| Other Income Expense | $583,000 | $549,000 | $-384,000 | $-792,000 |
| Other Non Operating Income Expenses | $680,000 | $549,000 | $-354,000 | $606,000 |
| Operating Expense | $24,090,000 | $18,406,000 | $21,250,000 | $18,540,000 |
| General And Administrative Expense | $12,049,000 | $10,269,000 | $12,184,000 | $8,119,000 |
| Selling And Marketing Expense | - | - | $783,000 | $1,051,000 |
| Interest Expense | - | - | - | $0 |
| Net Non Operating Interest Income Expense | - | - | - | $0 |
| Interest Expense Non Operating | - | - | - | $0 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-22,704,000 | $-15,973,000 | $-21,413,000 | $-18,835,000 |
| Normalized Income | $-22,607,000 | $-15,973,000 | $-21,383,000 | $-17,437,000 |
| Net Income From Continuing And Discontinued Operation | $-22,704,000 | $-15,973,000 | $-21,413,000 | $-18,835,000 |
| Total Operating Income As Reported | $-23,287,000 | $-16,522,000 | $-21,029,000 | $-18,043,000 |
| Net Income Common Stockholders | $-22,704,000 | $-24,623,000 | $-22,211,000 | $-18,835,000 |
| Net Income | $-22,704,000 | $-15,973,000 | $-21,413,000 | $-18,835,000 |
| Net Income Including Noncontrolling Interests | $-22,704,000 | $-15,973,000 | $-21,413,000 | $-18,835,000 |
| Net Income Continuous Operations | $-22,704,000 | $-15,973,000 | $-21,413,000 | $-18,835,000 |
| Pretax Income | $-22,704,000 | $-15,973,000 | $-21,413,000 | $-18,835,000 |
| Special Income Charges | $-97,000 | $0 | $-30,000 | $-1,398,000 |
| Operating Income | $-23,287,000 | $-16,522,000 | $-21,029,000 | $-18,043,000 |
| Gross Profit | $803,000 | $1,884,000 | $221,000 | $497,000 |
| Net Interest Income | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-1.29 | $-2.62 | $-10.22 | $-9.00 |
| Basic EPS | $-1.29 | $-2.62 | $-10.22 | $-9.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-21,964,000 | $-15,564,000 | $-20,053,000 | $-15,752,000 |
| Total Unusual Items | $-97,000 | $0 | $-30,000 | $-1,398,000 |
| Total Unusual Items Excluding Goodwill | $-97,000 | $0 | $-30,000 | $-1,398,000 |
| Reconciled Depreciation | $1,226,000 | $958,000 | $946,000 | $893,000 |
| EBITDA (Bullshit earnings) | $-22,061,000 | $-15,564,000 | $-20,083,000 | $-17,150,000 |
| EBIT | $-23,287,000 | $-16,522,000 | $-21,029,000 | $-18,043,000 |
| Diluted Average Shares | $17,576,551 | $9,411,164 | $2,173,490 | $2,096,903 |
| Basic Average Shares | $17,576,551 | $9,411,164 | $2,173,490 | $2,096,903 |
| Diluted NI Availto Com Stockholders | $-22,704,000 | $-24,623,000 | $-22,211,000 | $-18,835,000 |
| Otherunder Preferred Stock Dividend | $0 | $8,650,000 | $798,000 | $0 |
| Gain On Sale Of Ppe | $-97,000 | $0 | - | - |
| Research And Development | $12,041,000 | $8,137,000 | $9,066,000 | $9,370,000 |
| Selling General And Administration | $12,049,000 | $10,269,000 | $12,184,000 | $9,170,000 |
| Other Gand A | $12,049,000 | $10,269,000 | $12,184,000 | $8,119,000 |
| Other Special Charges | - | - | $30,000 | $1,398,000 |
Fetched: 2026-06-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $3,390,000 | $19,486,000 | $4,454,000 | $18,094,000 |
| Total Assets | $10,261,000 | $25,558,000 | $12,078,000 | $27,413,000 |
| Total Non Current Assets | $4,810,000 | $5,934,000 | $6,230,000 | $7,133,000 |
| Other Non Current Assets | $176,000 | $202,000 | $193,000 | $244,000 |
| Goodwill And Other Intangible Assets | $2,285,000 | $2,401,000 | $2,287,000 | $2,409,000 |
| Other Intangible Assets | $2,285,000 | $2,401,000 | $2,287,000 | $2,409,000 |
| Current Assets | $5,451,000 | $19,624,000 | $5,848,000 | $20,280,000 |
| Other Current Assets | $686,000 | $308,000 | $376,000 | $404,000 |
| Receivables | $104,000 | $84,000 | $111,000 | $218,000 |
| Accounts Receivable | $104,000 | $25,000 | $15,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $4,661,000 | $19,232,000 | $5,361,000 | $19,658,000 |
| Cash And Cash Equivalents | $4,661,000 | $19,232,000 | $4,949,000 | $10,503,000 |
| Other Receivables | - | $59,000 | $96,000 | $218,000 |
| Current Deferred Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $824,000 | $1,447,000 | $2,041,000 | $2,605,000 |
| Long Term Debt And Capital Lease Obligation | $169,000 | $824,000 | $1,448,000 | $2,041,000 |
| Current Debt And Capital Lease Obligation | $655,000 | $623,000 | $593,000 | $564,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,586,000 | $3,671,000 | $5,337,000 | $6,910,000 |
| Total Non Current Liabilities Net Minority Interest | $499,000 | $1,089,000 | $1,448,000 | $2,041,000 |
| Other Non Current Liabilities | $330,000 | $265,000 | - | - |
| Current Liabilities | $4,087,000 | $2,582,000 | $3,889,000 | $4,869,000 |
| Current Deferred Liabilities | $40,000 | $40,000 | $506,000 | $506,000 |
| Payables And Accrued Expenses | $3,392,000 | $1,919,000 | $2,790,000 | $2,401,000 |
| Payables | $423,000 | $99,000 | $638,000 | $1,751,000 |
| Accounts Payable | $423,000 | $99,000 | $638,000 | $1,751,000 |
| Other Current Liabilities | - | - | - | $1,398,000 |
| Current Notes Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $5,675,000 | $21,887,000 | $6,741,000 | $20,503,000 |
| Total Equity Gross Minority Interest | $5,675,000 | $21,887,000 | $6,741,000 | $20,503,000 |
| Stockholders Equity | $5,675,000 | $21,887,000 | $6,741,000 | $20,503,000 |
| Retained Earnings | $-132,311,000 | $-109,607,000 | $-84,984,000 | $-62,773,000 |
| Other Equity Interest | - | - | $-100,000 | $-100,000 |
| Gains Losses Not Affecting Retained Earnings | - | - | $0 | $-357,000 |
| Other Equity Adjustments | - | - | - | $-357,000 |
| Other | ||||
| Ordinary Shares Number | $22,929,341 | $14,891,446 | $2,510,730 | $2,101,840 |
| Share Issued | $22,929,341 | $14,891,446 | $2,510,730 | $2,101,840 |
| Tangible Book Value | $3,390,000 | $19,486,000 | $4,454,000 | $18,094,000 |
| Invested Capital | $5,675,000 | $21,887,000 | $6,741,000 | $20,503,000 |
| Working Capital | $1,364,000 | $17,042,000 | $1,959,000 | $15,411,000 |
| Capital Lease Obligations | $824,000 | $1,447,000 | $2,041,000 | $2,605,000 |
| Total Capitalization | $5,675,000 | $21,887,000 | $6,741,000 | $20,503,000 |
| Additional Paid In Capital | $137,964,000 | $131,480,000 | $91,823,000 | $83,712,000 |
| Capital Stock | $22,000 | $14,000 | $2,000 | $21,000 |
| Common Stock | $22,000 | $14,000 | $2,000 | $21,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $169,000 | $824,000 | $1,448,000 | $2,041,000 |
| Current Deferred Revenue | $40,000 | $40,000 | $506,000 | $506,000 |
| Current Capital Lease Obligation | $655,000 | $623,000 | $593,000 | $564,000 |
| Current Accrued Expenses | $2,969,000 | $1,820,000 | $2,152,000 | $650,000 |
| Net PPE | $2,349,000 | $3,331,000 | $3,750,000 | $4,480,000 |
| Accumulated Depreciation | $-5,823,000 | $-5,174,000 | $-4,440,000 | $-3,727,000 |
| Gross PPE | $8,172,000 | $8,505,000 | $8,190,000 | $4,480,000 |
| Leases | $4,410,000 | $4,402,000 | $4,328,000 | $4,328,000 |
| Machinery Furniture Equipment | $3,249,000 | $3,221,000 | $2,641,000 | $2,348,000 |
| Buildings And Improvements | $513,000 | $882,000 | $1,221,000 | $1,531,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Properties | - | $882,000 | $1,221,000 | $2,949,000 |
| Other Short Term Investments | - | $0 | $412,000 | $9,155,000 |
Fetched: 2026-06-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-19,240,000 | $-14,860,000 | $-19,696,000 | $-14,825,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-18,645,000 | $-13,868,000 | $-19,002,000 | $-13,969,000 |
| Cash Flow From Continuing Operating Activities | $-18,645,000 | $-13,868,000 | $-19,002,000 | $-13,969,000 |
| Operating Gains Losses | $97,000 | - | - | $1,398,000 |
| Investing Activities | ||||
| Capital Expenditure | $-595,000 | $-992,000 | $-694,000 | $-856,000 |
| Investing Cash Flow | $-595,000 | $-640,000 | $8,186,000 | $-677,000 |
| Cash Flow From Continuing Investing Activities | $-595,000 | $-640,000 | $8,186,000 | $-677,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $4,980,000 | $12,866,000 | $5,338,000 | $0 |
| Financing Cash Flow | $4,669,000 | $28,791,000 | $5,262,000 | $-509,000 |
| Cash Flow From Continuing Financing Activities | $4,669,000 | $28,791,000 | $5,262,000 | $-509,000 |
| Net Other Financing Charges | $-311,000 | $-266,000 | $-174,000 | $-511,000 |
| Net Common Stock Issuance | $4,980,000 | $12,866,000 | $5,338,000 | $0 |
| Common Stock Issuance | $4,980,000 | $12,866,000 | $5,338,000 | $0 |
| Other | ||||
| End Cash Position | $4,661,000 | $19,232,000 | $4,949,000 | $10,503,000 |
| Beginning Cash Position | $19,232,000 | $4,949,000 | $10,503,000 | $25,658,000 |
| Changes In Cash | $-14,571,000 | $14,283,000 | $-5,554,000 | $-15,155,000 |
| Proceeds From Stock Option Exercised | $0 | $16,191,000 | $98,000 | $2,000 |
| Net Investment Purchase And Sale | $0 | $352,000 | $8,880,000 | $179,000 |
| Sale Of Investment | $0 | $352,000 | $8,880,000 | - |
| Net Intangibles Purchase And Sale | $-350,000 | $-337,000 | $-393,000 | $-287,000 |
| Purchase Of Intangibles | $-350,000 | $-337,000 | $-393,000 | $-287,000 |
| Net PPE Purchase And Sale | $-245,000 | $-655,000 | $-301,000 | $-569,000 |
| Purchase Of PPE | $-245,000 | $-655,000 | $-301,000 | $-569,000 |
| Interest Received Cfo | $0 | $60,000 | $220,000 | - |
| Change In Working Capital | $1,059,000 | $-1,241,000 | $321,000 | $238,000 |
| Change In Other Working Capital | $-254,000 | $-720,000 | $-254,000 | $110,000 |
| Change In Other Current Liabilities | $66,000 | $265,000 | $0 | - |
| Change In Other Current Assets | $25,000 | $-9,000 | $51,000 | $-15,000 |
| Change In Payables And Accrued Expense | $1,620,000 | $-872,000 | $389,000 | $429,000 |
| Change In Accrued Expense | $1,295,000 | $-332,000 | $1,502,000 | $-677,000 |
| Change In Payable | $325,000 | $-540,000 | $-1,113,000 | $1,106,000 |
| Change In Account Payable | $325,000 | $-540,000 | $-1,113,000 | $1,106,000 |
| Change In Prepaid Assets | $-378,000 | $68,000 | $28,000 | $-122,000 |
| Change In Receivables | $-20,000 | $27,000 | $107,000 | $-164,000 |
| Stock Based Compensation | $1,677,000 | $2,328,000 | $2,032,000 | $2,167,000 |
| Depreciation Amortization Depletion | $1,226,000 | $958,000 | $946,000 | $893,000 |
| Depreciation And Amortization | $1,226,000 | $958,000 | $946,000 | $893,000 |
| Net Income From Continuing Operations | $-22,704,000 | $-15,973,000 | $-21,413,000 | $-18,835,000 |
| Asset Impairment Charge | - | $0 | $290,000 | $0 |
| Other Non Cash Items | - | - | $-1,398,000 | - |
| Unrealized Gain Loss On Investment Securities | - | - | $220,000 | $170,000 |
| Repayment Of Debt | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Short Term Debt Issuance | - | - | - | $0 |
| Short Term Debt Payments | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Payments | - | - | - | $0 |
| Sale Of PPE | - | - | - | $0 |
| Gain Loss On Investment Securities | - | - | - | $1,398,000 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
| Issuance Of Debt | - | - | - | - |
| Short Term Debt Issuance | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-24